Agnieszka Potęga

发表

The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s

C. Wolf, Á. Kot-Wasik, Sébastien Ronseaux, 2011, Drug Metabolism and Disposition.

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti‐tumour imidazoacridinone C‐1311 in human hepatoma cells

M. Pawłowska, E. Augustin, Z. Mazerska, 2013, Cell biology international.

Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation

Agnieszka Potęga, 2022, Molecules.

Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053.

E. Paluszkiewicz, Szymon Paczkowski, Z. Mazerska, 2021, Journal of pharmaceutical and biomedical analysis.

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305☆

D. Żelaszczyk, Z. Mazerska, Agnieszka Potęga, 2020, Journal of pharmaceutical analysis.

Acid–Base Equilibrium and Self-Association in Relation to High Antitumor Activity of Selected Unsymmetrical Bisacridines Established by Extensive Chemometric Analysis

Z. Mazerska, Katarzyna Szwarc-Karabyka, W. Andrałojć, 2022, Molecules.

Electrochemical simulation of metabolism for antitumor‐active imidazoacridinone C‐1311 and in silico prediction of drug metabolic reactions

D. Żelaszczyk, Z. Mazerska, Agnieszka Potęga, 2019, Journal of pharmaceutical and biomedical analysis.

Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry

Á. Kot-Wasik, A. Nowicka, Z. Mazerska, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

A. Kasprzak, A. Nowicka, E. Paluszkiewicz, 2023, Pharmaceutics.

Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: Characteristics of non-enzymatic and glutathione S-transferase-mediated reactions

Z. Mazerska, Agnieszka Potęga, Michał Kosno, 2021, Journal of Pharmaceutical Analysis.

Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells.

K. Jagiello, C. Henderson, Anna Skwarska, 2012, Biochemical pharmacology.

Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

A. Nowicka, A. Kowalczyk, M. Pawłowska, 2021, Pharmaceuticals.

Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes

Z. Mazerska, Barbara Fedejko-Kap, Agnieszka Potęga, 2016, Pharmacological reports : PR.

Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305

Z. Mazerska, Barbara Fedejko-Kap, Agnieszka Potęga, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

New, fast and cheap prediction tests for BRCA1 gene mutations identification in clinical samples

A. Kudelski, A. Nowicka, A. Kowalik, 2023, Scientific reports.

Electrochemistry/mass spectrometry (EC/MS) for fast generation and identification of novel reactive metabolites of two unsymmetrical bisacridines with anticancer activity.

U. Karst, E. Paluszkiewicz, Agnieszka Potęga, 2023, Journal of pharmaceutical and biomedical analysis.

In Vitro Enzyme Kinetics and NMR-Based Product Elucidation for Glutathione S-Conjugation of the Anticancer Unsymmetrical Bisacridine C-2028 in Liver Microsomes and Cytosol: Major Role of Glutathione S-Transferase M1-1 Isoenzyme

E. Paluszkiewicz, W. Andrałojć, Agnieszka Potęga, 2023, Molecules.